Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain

Journal of Neuroscience

Volumn 35, Issue 14, 2015, Pages 5851-5859

  Liu, Chia Chen ^a,b   Hu, Jin ^a,b   Tsai, Chih Wei ^a   Yue, Mei ^a   Melrose, Heather L ^a   Kanekiyo, Takahisa ^a   Bu, Guojun ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b XIAMEN UNIVERSITY   (China)

Author keywords

Alzheimer s disease; Apolipoprotein e; Glucose metabolism; Insulin signaling; LRP1

Indexed keywords

GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN RECEPTOR; LRP1 PROTEIN, MOUSE; SLC2A3 PROTEIN, MOUSE; SLC2A4 PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOTINYLATION; BLOOD BRAIN BARRIER; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; FLOW CYTOMETRY; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING; ANIMAL; BRAIN; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TRANSFORMED CELL LINE; TRANSGENIC MOUSE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELL LINE, TRANSFORMED; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORTER TYPE 3; GLUCOSE TRANSPORTER TYPE 4; INSULIN; MICE; MICE, TRANSGENIC; NEURONS; PROTEIN TRANSPORT; RECEPTORS, LDL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84929380062     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5180-14.2015     Document Type: Article

References (63)

1. Ardestani A, Paroni F, Azizi Z, Kaur S, Khobragade V, Yuan T, Frogne T, Tao W, Oberholzer J, Pattou F, Kerr Conte J, Maedler K (2014) MST1 is a key regulator of beta cell apoptosis and dysfunction in diabetes. Nat Med 20:385–397.CrossRef Medline
2. Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S (2011) Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 68:51–57.CrossRef Medline
3. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5:64–74.CrossRef Medline
4. Blomstrand F, Giaume C (2006) Kinetics of endothelin-induced inhibition and glucose permeability of astrocyte gap junctions. J Neurosci Res 83: 996–1003.CrossRef Medline
5. Brands AM, Biessels GJ, de Haan EH, Kappelle LJ, Kessels RP (2005) The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care 28:726–735.CrossRef Medline
6. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10:333–344.CrossRef Medline
7. Bu G, Geuze HJ, Strous GJ, Schwartz AL (1995) 39 kDa receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein. EMBO J 14:2269–2280.CrossRef Medline
8. Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S (2015) Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia. J Alzheimers Dis 44: 897–906.CrossRef Medline
9. Cohen AD, Klunk WE (2014) Early detection of Alzheimer’s disease using PiB and FDG PET. Neurobiol Dis 72:117–122.CrossRef Medline
10. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69:29–38.CrossRef Medline
11. de la Monte SM, Wands JR (2008) Alzheimer’s disease is type 3 diabetesevidence reviewed. J Diabetes Sci Technol 2:1101–1113.CrossRef Medline
12. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B, Fowler J (2001) Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A 98:10966–10971.CrossRef Medline
13. Dhamoon MS, Noble JM, Craft S (2009) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 72:292–293; author reply 293–294.CrossRef Medline
14. Foster NL, Wang AY, Tasdizen T, Fletcher PT, Hoffman JM, Koeppe RA (2008) Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer’s disease. Alzheimers Dement 4 [Suppl 1]:S29–S36.CrossRef Medline
15. Gan M, Jiang P, McLean P, Kanekiyo T, Bu G (2014) Low-density lipopro tein receptor-related protein 1 (LRP1) regulates the stability and function of GluA1 alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor in neurons. PLoS One 9:e113237.CrossRef Medline
16. Gerozissis K (2003) Brain insulin: regulation, mechanisms of action and functions. Cell Mol Neurobiol 23:1–25.CrossRef Medline
17. Herz J, Strickland DK (2001) LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 108:779–784.CrossRef Medline
18. Ho L, Yemul S, Knable L, Katsel P, Zhao R, Haroutunian V, Pasinetti GM (2012) Insulin receptor expression and activity in the brains of nondiabetic sporadic Alzheimer’s disease cases. Int J Alzheimers Dis 2012: 321280.CrossRef Medline
19. Hong H, Liu LP, Liao JM, Wang TS, Ye FY, Wu J, Wang YY, Wang Y, Li YQ, Long Y, Xia YZ (2009) Downregulation of LRP1 [correction of LPR1] at the blood–brain barrier in streptozotocin-induced diabetic mice. Neuropharmacology 56:1054–1059.CrossRef Medline
20. Hoyer S (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490:115–125.CrossRef Medline
21. Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, Launer LJ (2008) Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol 65:89–93.CrossRef Medline
22. Jagust W, Reed B, Mungas D, Ellis W, Decarli C (2007) What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69:871–877.CrossRef Medline
23. Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53:474– 481.CrossRef Medline
24. Jedrychowski MP, Gartner CA, Gygi SP, Zhou L, Herz J, Kandror KV, Pilch PF (2010) Proteomic analysis of GLUT4 storage vesicles reveals LRP1 to be an important vesicle component and target of insulin signaling. J Biol Chem 285:104–114.CrossRef Medline
25. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846.CrossRef Medline
26. Kandror KV, Pilch PF (2011) The sugar is sIRVed: sorting Glut4 and its fellow travelers. Traffic 12:665–671.CrossRef Medline
27. Kanekiyo T, Bu G (2014) The low-density lipoprotein receptor-related protein 1 and amyloid-beta clearance in Alzheimer’s disease. Front Aging Neurosci 6:93.CrossRef Medline
28. Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, Shinohara M,Holtzman DM, Bu G (2013) Neuronal clearance of amyloid-beta by endocytic receptor LRP1. J Neurosci 33:19276–19283.CrossRef Medline
29. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH (2000) Modulation of amyloid beta-protein clearance and Alzheimer’s disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 106: 1159–1166.CrossRef Medline
30. Kleinridders A, Ferris HA, Cai W, Kahn CR (2014) Insulin action in brain regulates systemic metabolism and brain function. Diabetes 63:2232– 2243.CrossRef Medline
31. Ko KW, Avramoglu RK, McLeod RS, Vukmirica J, Yao Z (2001) The insulin-stimulated cell surface presentation of low density lipoprotein receptor-related protein in 3T3–L1 adipocytes is sensitive to phosphatidylinositide 3-kinase inhibition. Biochemistry 40:752–759.CrossRef Medline
32. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK (2008) LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 88:887–918.CrossRef Medline
33. Liposits Z, Merchenthaler I, Wetsel WC, Reid JJ, Mellon PL, Weiner RI, Negro-Vilar A (1991) Morphological characterization of immortalized hypothalamic neurons synthesizing luteinizing hormone-releasing hormone. Endocrinology 129:1575–1583.CrossRef Medline
34. Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106–118.CrossRef Medline
35. Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G (2007) Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56:66–78.CrossRef Medline
36. Liu Q, Trotter J, Zhang J, Peters MM, Cheng H, Bao J, Han X, Weeber EJ, Bu G (2010) Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J Neurosci 30:17068–17078.CrossRef Medline
37. Maier W, Bednorz M, Meister S, Roebroek A, Weggen S, Schmitt U, Pietrzik CU (2013) LRP1 is critical for the surface distribution and internalization of the NR2B NMDA receptor subtype. Mol Neurodegener 8:25.CrossRef Medline
38. McEwen BS, Reagan LP (2004) Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol 490:13–24.CrossRef Medline
39. Minoshima S (2003) Imaging Alzheimer’s disease: clinical applications. Neuroimaging Clin North Am 13:769–780.CrossRef Medline
40. Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31:224–243. CrossRef Medline Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, Laska E, Rusinek H,CrossRef Medline
41. de Leon MJ (2008) Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 29:676–692.CrossRef Medline
42. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, Pirraglia E, De Santi S, Reisberg B, Wisniewski T, de Leon MJ (2009) FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease. Eur J Nucl Med Mol Imaging 36:811–822.CrossRef Medline
43. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ (2010) Preclinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis 20:843–854.CrossRef Medline
44. Park CR (2001) Cognitive effects of insulin in the central nervous system. Neurosci Biobehav 25:311–323.CrossRef Medline
45. Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 51:1256–1262.CrossRef Medline
46. Poirier J, Miron J, Picard C, Gormley P, Theroux L, Breitner J, Dea D (2014) Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer’s disease. Neurobiol Aging 35 [Suppl 2]:S3–S10.CrossRef Medline
47. Porras OH, Loaiza A, Barros LF (2004) Glutamate mediates acute glucose transport inhibition in hippocampal neurons. J Neurosci 24:9669–9673.CrossRef Medline
48. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8:247–268.CrossRef Medline
49. Rohlmann A, Gotthardt M, Hammer RE, Herz J (1998) Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest 101:689–695.CrossRef Medline
50. Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P (1994) Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer’s disease. Ann Neurol 35:546–551.CrossRef Medline
51. Sims-Robinson C, Kim B, Rosko A, Feldman EL (2010) How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6:551–559.CrossRef Medline
52. Skeberdis VA, Lan J, Zheng X, Zukin RS, Bennett MV (2001) Insulin promotes rapid delivery of N-methyl-D-aspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci U S A 98:3561–3566.CrossRef Medline
53. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease: is this type 3 diabetes? J Alzheimers Dis 7:63–80.CrossRef Medline
54. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, Weinberg RA, Novina CD (2003) Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9:493–501.CrossRef Medline
55. Stolk RP, Breteler MM, Ott A, Pols HA, Lamberts SW, Grobbee DE, Hofman A (1997) Insulin and cognitive function in an elderly population: the Rotterdam Study. Diabetes Care 20:792–795.CrossRef Medline
56. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122:1316–1338.CrossRef Medline
57. Tamaki C, Ohtsuki S, Terasaki T (2007) Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol Pharmacol 72:850–855.CrossRef Medline
58. Thies W, Bleiler L (2013) 2013 Alzheimer’s disease facts and figures. Alzheimers Dement 9:208–245.CrossRef Medline
59. Tsien JZ, Chen DF, Gerber D, Tom C, Mercer EH, Anderson DJ, Mayford M, Kandel ER, Tonegawa S (1996) Subregion- and cell type-restricted gene knockout in mouse brain. Cell 87:1317–1326.CrossRef Medline
60. Yamada K, Nakata M, Horimoto N, Saito M, Matsuoka H, Inagaki N (2000) Measurement of glucose uptake and intracellular calcium concentration in single, living pancreatic beta-cells. J Biol Chem 275:22278–22283.CrossRef Medline
61. Yamada K, Saito M, Matsuoka H, Inagaki N (2007) A real-time method of imaging glucose uptake in single, living mammalian cells. Nat Protoc 2:753–762.CrossRef Medline
62. Zhao W, Chen H, Xu H, Moore E, Meiri N, Quon MJ, Alkon DL (1999) Brain insulin receptors and spatial memory: correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem 274:34893–34902.CrossRef Medline
63. Zhou J, Martin RJ, Tulley RT, Raggio AM, McCutcheon KL, Shen L, Danna SC, Tripathy S, Hegsted M, Keenan MJ (2008) Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am J Physiol Endocrinol Metab 295:E1160– E1166.CrossRef Medline